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INTRODUCTION 
              Fine needle aspiration (FNA) has proven to be a very effective means 
of obtaining tissue from many different body sites for diagnosis. Fine needle 
aspiration (FNA) of liver in diagnosing hepatocellular carcinoma and liver 
metastases is proven to be a safe, sensitive and specific method when guided by 
ultrasound (US) or computed tomography (CT). Numerous studies have 
reported a sensitivity between 67% and 100% and accuracy rate as high as 
96%.1   This diagnostic method was first applied to the liver as early as 1895. 
FNA is used predominantly for diagnosing mass lesions when there is a 
question of a neoplastic process, either primary or metastatic. The procedure, 
however, has not been successful in identifying diffuse liver disorders, such as 
hepatitis or cirrhosis. The risk of malignancy growing along the biopsy tract is 
small but real, with a reported incidence up to 1:1,000 in abdominal biopsies.  
Severe complications and mortality rate are low, and was reported in 0.04% to 
0.05% and 0.004% to 0.008% respectively in two large reviews which included 
a combined total of more than 65,000 abdominal biopsies.2 
 In most cases, the diagnosis presents no significant challenges to the 
pathologist.  Problems tend to occur when the lesion is a very well 
differentiated hepatocellular process, which the pathologist must identify as 
benign or malignant or a poorly differentiated neoplasm that arises in a patient 
without any other known malignancy, for which the pathologist must determine 
if it is a primary or metastatic lesion. 
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            Hepatic masses are increasingly being detected on radiography with the 
use of sophisticated abdominal imaging studies. Specific diagnoses can often 
be suspected based on sensitive radiographic imaging techniques (computed 
tomography, magnetic resonance imaging) coupled with clinical data and blood 
investigations. Except for hemangiomas, however, histopathological diagnosis 
remains the gold standard in determining tumor classification and appropriate 
clinical treatment.  
             The varied array of primary benign and malignant masses and the high 
rates of metastases to the liver account for much of the diagnostic difficulty 
encountered. Primary tumors can be solid or cystic and can arise from 
epithelium (hepatocyte, bile duct epithelium, neuroendocrine cells) or 
mesenchymal cells (principally endothelium), or heterotopic tissues. The 
majority of malignant hepatic neoplasms in normal liver represent metastatic 
carcinoma derived from virtually any primary site, whereas in patients with 
cirrhosis, hepatocellular carcinoma (HCC) is more common.  
              Although diagnosis of the primary hepatic neoplasms is often 
straightforward in resection specimens, definitive classification of a biopsy 
specimen (core or fine-needle aspiration) showing evidence of benign-
appearing hepatocytes can be quite difficult. The most common problem 
encountered in biopsy specimens is in making the distinction between HCC 
and metastatic carcinoma. The selective use of immunohistochemistry can be 
quite useful in this situation.  
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Since fine-needle aspiration (FNA) has assumed a primary diagnostic 
role in the evaluation of hepatic masses, this prospective study has been done 
focussing on the value of percutaneous FNA in the diagnosis of focal liver 
lesions and their radiological and histological correlation . 
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AIM OF STUDY 
1. To investigate the value of percutaneous FNA in the diagnosis of liver 
tumors. 
2. To evaluate the correlation of FNA diagnosis of focal liver lesions with 
that of radiological and histopathological diagnosis. 
3. To predict the possible primary  site in cases of metastatic neoplasm to 
the liver. 
4. To confirm the diagnosis of metastases from a known primary site. 
5. To evaluate the role of immunohistochemistry on selected problematic 
cases. 
6. To determine the sensitivity and specificity of cytological diagnosis  
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REVIEW OF LITERATURE 
HISTORY 
Hepatic aspiration was performed as long ago as in 1833, when Robert 
and Biet reported its use in the treatment of hepatic suppuration and hydatid 
disease.3,4 
Needle biopsy using aspiration was first employed in 1883 by Paul 
Ehrlich (cited in Schupfer 1907) in a study of glycogen content of diabetic 
liver. 5 
Aspiration using very fine needle to evaluate cytological specimens was 
first used by Lucatello in 1895 (cited in Lundquist 1971).6 At the beginning of 
20th century , needle biopsy was accompanied by a high mortality rate. In 1935 
Frola in France tried to reduce complications by using a needle which 
measured 0.5mm in diameter. Since then in 1939 Iverson and Roholm from 
Denmark, Baron from USA and other workers from northern continental 
Europe investigated on cytological methods.7 
In 1966, Nils So Derstrom 8 published a series of samples in which his 
observation on metastatic carcinoma and myeloid metaplasia was helpful in 
clinical diagnosis. Lundquist published several papers including a thesis on his 
experience of intrahepatic tumors, acute hepatitis, cirrhosis, iron overload, fatty 
infiltration and other conditions. 
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            In 1967, Sherlock et al 9 proved that more neoplasms are detected when 
cytological examination is performed in addition to histology. This included 
fluid from needles and syringes and touch preparations of biopsy tissue. 
In 1972, Rasmussen et al10 described a method for FNA of liver 
metastases under direct guidance by ultrasonic scanning. They found that FNA 
cytology had a higher diagnostic rate than routine liver biopsy using the 
Menghini method. 
In 1976, Haaga et al 11 described a method for precise localization of 
lesion by US/CT. This allowed accurate positioning of needle when lesions 
were very small and reduced the rate of false negativity. Over the last 15 to 20 
years of the 20th century, it became increasingly clear that percutaneous FNA of 
single or multiple focal liver lesions demonstrated by palpation, nuclear scan , 
U/S or CT  is both accurate and safe .12,13 
Caution should be exerted when taking a biopsy in a patient with an 
obstructive biliary tree due to the increased risk of bile leakage. Ascites has 
also been considered a relative contraindication to biopsy. However, in a 
comparative study, Murphy et al (1988) concluded that the risk is not higher 
than biopsies done in its absence. 
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ALGORITHMIC APPROACH TO FOCAL LIVER LESIONS 
1. Establish category of clinical presentation 
2. Establish category of radiological findings 
3. Establish nature of FNA findings 
4. Further confirm nature of FNA findings by Histopathological 
examination(HPE) 
5. Establish final diagnosis based on multidisciplinary approach    
1. CLINICAL DIAGNOSIS 
The clinical diagnosis of a patient presenting with a liver mass rests on 
clinical examination of the patient and investigations like hematological 
analysis including coagulation profile, urine tests, liver function tests, viral 
markers, serum alpha-fetoprotein (AFP) and evaluation for cirrhosis and biliary 
tract disease. The clinical diagnosis of malignancy was 58% according to D.K. 
Das.14  
2.  RADIOLOGICAL FINDINGS  
The clinical diagnosis of malignancy improved with imaging.14 
Radiological correlation of liver masses by various imaging techniques like 
Ultrasonogram (US), Computerised Tomography (CT) and Magnetic 
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Resonance Imaging (MRI) have assumed a primary role in the evaluation of 
hepatic masses. The imaging  findings of various common focal liver lesions 
are discussed below . These may be unifocal or multifocal and solid or cystic. 
Hepatocellular carcinoma 
Ultrasound shows focal form of HCC as a rounded or lobular lesion with 
often high level echoes and becoming heterogenous with enlargement. Invasion 
of hepatic veins or portal veins are demonstrated as echogenic foci within the 
vessel. On non-contrast CT, HCC appears as a solitary mass or multiple masses 
that are hypodense relative to normal hepatic parenchyma. Calcification is seen 
in less than 10%. Following administration of intravenous contrast, HCC is 
normally hyperdense in arterial phase due to its vascularity and hypo or 
isodense compared to  hepatic parenchyma in portal phase. Multifocal HCC 
appears as low density lesion in unenhanced CT, showing peripheral 
enhancement and heterogenous internal density on contrast.15  
Fibrolamellar hepatocellular carcinoma: 
On CT, appears as large well defined low attenuation mass. The central 
stellate scar shows lower attenuation appearance with calcification occurring 
within the scar. After IV contrast administration, enhancement of tumor occurs 
because of its perivascularity.  A distinguishing feature from HCC is its lack of 
hemorrhage and necrosis. 
 15 
Intrahepatic cholangiocarcinoma: 
It is an adenocarcinoma arising from small intrahepatic ducts. 
Ultrasonography demonstrates mass with irregular margins that is slightly 
hyperechoeic due to fibrotic tissue. CT shows a hypo attenuating mass with 
irregular margins that shows mild peripheral enhancement. Slow diffusion of 
contrast medium from vascular to interstitial space results in delayed and 
prolonged enhancement. 
Metastases: 
The liver is second in frequency to the lungs as a site of involvement by 
distant metastases. Although presence of multiple hepatic masses is suggestive 
of metastatic disease, a variety of benign hepatic lesions can be multiple like 
cysts, hemangiomas, biliary hamartomas, fungal abscesses and multicentric 
HCC. On ultrasound, they may be echopoor or echogenic, while mixed patterns 
as well as fluid regions following necrosis also occur. Metastases are 
exclusively supplied by hepatic artery. Echogenic lesions are typical of 
secondaries from urogenital and gastrointestinal tract. 
On CT, most metastases are hypervascular and appear hypodense 
relative to normal  liver, that shows rim enhancement representing vascularized 
viable tumor periphery. Centrally low attenuation may be present if a lesion has 
central necrosis or cystic change .The borders of metastases may be sharply 
defined, ill defined or nodular and portal vein invasion is best displayed after 
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intravenous contrast administration. Hyperdense metastases are usually hyper 
vascular in nature that appears as a hyper attenuating lesion.16 Some metastases 
may have a cystic appearance as seen with mucinous adenocarcinoma of the 
colon and cystadenocarcinoma of the ovary. In many instances, a preoperative 
diagnosis can be achieved with a high degree of accuracy based on non-
invasive imaging techniques and close clinical correlation. The solid or cystic 
nature of the lesion, number, size and location of the lesions, absence or 
presence of hepatomegaly, cirrhosis, steatosis, regional lymphadenopathy and 
calculi and status of the biliary tract are important clues to the final diagnosis. 
FNA is useful in defining those lesions without characteristic imaging 
appearance. 
Hepatic adenoma 
Ultrasound appearance is often non-specific and mimics other benign 
and malignant lesions. It appears as a well demarcated hyperechoeic mass. 
Heterogenous echogenicity may result from hemorrhage or necrosis. Non 
contrast CT shows well demarcated, hypodense lesions, although hemorrhage 
and necrosis result in hyperdense lesion. On contrast, early phase peripheral 
enhancement with subsequent centripetal contrast flow is seen. 
3.  FINE NEEDLE ASPIRATION FINDINGS  
Liver aspirates can come from malignant or benign conditions of 
hepatocellular or non-hepatocellular origin. 
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FNA of normal/reactive liver 
The liver parenchyma comprises a heterogeneous population of 
hepatobiliary and related cells, namely, hepatocytes, bile duct epithelium, 
Kupffer, endothelial, mesothelial and inflammatory cells.17 Hepatocytes often 
contain intracytoplasmic inclusions such as fat vacuoles, Mallory bodies and 
hyaline bodies; as well as intranuclear cytoplasmic inclusions. Pigments such 
as lipofuscin, bile and iron may be present. 
FNA of liver cell dysplasia 
Hepatocytes with large cell change, exhibit both cell and nuclear 
enlargement with nuclear atypia but retaining the normal nuclear-cytoplasmic 
ratio (N/C) of ≤ 1/3. On the other hand, in small cell change, with precancerous 
link to HCC, the hepatocytes are small and monotonous with subtle increase in 
N/C ratio. 
FNA of Hepatocellular carcinoma 
With regard to HCC, FNA is accurate with a sensitivity rate of 80 to 
95% and a specificity rate of 100%.18,19,20 
Needle aspiration biopsy may occasionally be used as an additional 
staging procedure to distinguish tumor invasion in the portal vein from simple 
thrombus.21                      
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The sensitivity of guided FNA for diagnosing hepatic malignancy in 
most recent series is 90% to 96%, with a specificity of 90% to 100%. False-
negative diagnoses of HCC are related either to very well differentiated tumors 
that are difficult to identify on the basis of cytology as being neoplastic or to 
poorly differentiated tumors that are difficult to distinguish as hepatocellular in 
origin. 
The presence of at least two of three criteria (polygonal cells with 
centrally placed nuclei, malignant cells separated by sinusoidal endothelial 
cells and bile) was considered by Bottles et al21 to be 97% sensitive and 100% 
specific for HCC compared with other malignancies. Cohen et al22 found that 
the presence of the following three features was 87% specific and 100% 
sensitive for the diagnosis of HCC versus non neoplastic conditions: an 
increased nuclear to cytoplasmic ratio, a trabecular pattern and atypical naked 
nuclei.  
Classic HCC is usually graded into well, moderately or poorly 
differentiated lesions. Histologic patterns comprise trabecular-sinusoidal, 
pseudoacinar and solid types; combinations are frequent.  
CYTOLOGICAL FEATURES 
• Hypercellular smears with uniformly granular pattern of spread of the 
cells. 
• Cohesive clusters of malignant hepatocytes with arborizing, tongue-like 
projections of broad cords (>2 cells thick) that may be wrapped by 
peripheral endothelium. 
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• Rows of transgressing endothelium in larger aggregates, “sinusoidal 
capillarization".23 
• Pseudoacini containing bile or pale secretions .  
• Hepatocytic characteristics include polygonal cells with well-defined 
borders, ample granular cytoplasm, central round nucleus, well-
delineated nuclear membrane, prominent nucleolus and fine, irregularly 
granular chromatin. Mitoses increase with nuclear grade.  
• Well differentiated HCC cells tend to be conspicuous by their small size, 
monotony, subtle increase in N/C ratio and nuclear crowding. Poorly 
differentiated HCC cells tend to be pleomorphic. 
• Atypical naked hepatocytic nuclei are seen. 
• Bile may be present within tumor cells or in canaliculi or pseudoacini. 
• Intracytoplasmic fat and glycogen vacuoles are common. 
Intracytoplasmic inclusions include hyaline, pale and Mallory bodies. 
Intranuclear cytoplasmic inclusions are seen. 
• Bile duct epithelial cells, if present, are few and far apart. Kupffer cells 
may be seen. 
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FNA of variants of hepatocellular carcinoma 
The variants of HCC include:  
HCC with fatty change; HCC- clear cell type; HCC- small cell type; 
HCC- undifferentiated type; HCC-spindle cell type; HCC- giant cell type; HCC 
with biliary differentiation.  
Fibrolamellar HCC: 
This occurs in non-cirrhotic livers of young patients and has a good 
prognosis. It comprises large, discohesive polygonal hepatocytes with abundant 
oncocytic cytoplasm and lamellar fibrosis. Pale bodies are common. 
Combined hepatocellular-cholangiocarcinoma (CHCC-CC):  
This is a rare tumor containing unequivocal elements of HCC and CC 
that are intimately admixed with a transitional component. The HCC cells are 
expected to be AFP and Hep Par 1-positive and show polyclonal CEA (pCEA) 
canalicular staining. The CC cells are AE1/3-positive and show brush 
border/diffuse cytoplasmic pCEA reactivity. The intermediate cells exhibit 
hybrid features with equivocal immunoprofiles. 
FNA of cholangiocarcinoma  
Intrahepatic Cholangiocarcinoma are rare and usually well to 
moderately differentiated adenocarcinomas with variable degree of 
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desmoplasia. Smears are variably cellular and shows sheets or clusters or 
tubular arrangement of cuboidal to columnar cells with eccentric large regular 
nuclei & prominent nucleoli. The cytoplasm shows fine vacuolization. The 
tumor cells are usually loosely cohesive ,and form acini. Hepatocytes are 
absent. 
FNA of metastatic  carcinoma 
          The liver is a common target for metastases. This makes the separation 
between primary and secondary malignancies all the more difficult, especially 
when the particular histologic subtype can arise in the liver as well.  
• Adenocarcinoma: Most are metastases from stomach, colorectum, 
pancreas, breast and lungs. Colorectal metastases have much tumor 
diathesis. Signet-ring cell adenocarcinomas are likely to be gastric in 
origin. Pancreaticobiliary tract adenocarcinomas can have squamous 
components. For any adenocarcinoma in hepatic aspirates, CC, HCC 
with pseudoacini and CHCC-CC have to be considered. 
• Squamous cell carcinoma: Most are metastatic or arise in the 
pancreaticobiliary tract. Large, spindly, "tadpole-shaped" or bizarre cells 
with dense cytoplasm, keratinization and much necrosis may be seen.  
• Spindle cell malignancy: Well-differentiated spindle cell tumors 
include leiomyosarcoma (LS), neurogenic tumors and 
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fibroblastic/stromal tumors including gastrointestinal stromal tumor 
(GIST). At the poorly differentiated end, Leiomyosarcoma, malignant 
fibrous histiocytoma, undifferentiated sarcoma or even sarcomatoid 
HCC or CC with a spindle cell component, have to be considered.  
• Others include Small/intermediate round cell malignancy, Pleomorphic 
cell malignancy and Clear cell malignancy 
FNA of Hepatic Adenoma: 
The smears are moderately cellular with monotonous cells resembling 
normal hepatocytes. The cells are uniform, polygonal with central round nuclei, 
with low nuclear cytoplasmic ratio. The cytoplasm is usually pale or 
vacuolated. The absence of bile duct epithelium is of diagnostic significance. 
FNA of Hepatoblastoma: 
Distinctive finding of FNA of fetal epithelial type includes highly 
cellular smears with small malignant cells in clusters, rosettes or trabeculae. 
The nuclei are round to oval and hyperchromatic with occasional nucleoli and 
scant cytoplasm. The embryonal type shows small oval to spindled cells with 
round to oval nuclei with prominent nucleoli, high N/C ratio and mitotic 
activity. Malignant mesenchymal tissue may be present. Extramedullary 
haemopoiesis is common. 
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4. HISTOPATHOLOGICAL FINDINGS (HPE) 
Histopathology is the gold standard for diagnosis of  any malignancy. 
The histopathological findings of common focal liver lesions are discussed 
below; 
Hepatocellular Carcinoma   
Malignant epithelial tumors account for about 98% of all primary 
hepatic malignancies, with HCC representing by far (about 85–90%) the single 
most common histologic type. The male-to-female ratio is 3:1 to 6:1. Patients 
usually show symptoms in the sixth or seventh decade of life.Virtually any 
condition associated with chronic hepatic injury (usually cirrhosis) may 
predispose toward HCC; hepatitis B, hepatitis C and alcohol are the other 
etiologic factors associated with an increased risk of HCC. HCC in the normal 
liver may also arise from hepatic adenoma or nodular regenerative hyperplasia.  
Periodic screening of patients with chronic liver disease for HCC, using 
a combination of ultrasonography and serum levels of AFP has become an 
accepted practice by hepatologists and has led to the diagnosis of many small 
(less than 2 cm) asymptomatic HCCs.   
Serum AFP levels remain the most useful marker for HCC. The level of 
serum des-U-carboxy prothrombin (DCP) has been suggested as an useful 
marker (60–90% sensitive, 85% specific); tests may be positive in nearly 30% 
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of AFP-seronegative patients. Serum AFP levels are elevated (more than 10 to 
20 ng/ml) in about 70% to 80% of patients(specificity 90%). Sustained AFP 
increases suggest HCC, but HCC can develop in the absence of elevated serum 
AFP. Malignant neoplasms often associated with very high levels (more than 
1,000 ng/ml) of serum AFP include HCC, HBL, and germ cell tumors 
containing a yolk sac component.   
Small Hepatocellular Carcinoma 
Virtually all tumors less than 1 cm consist of Well differentiated HCC 
with relatively thin trabeculae (less than or equal to three cells thick) of small 
hepatocytes showing little atypia. WD-HCC is distinguished from borderline 
foci/nodules, from which it may arise (nodule in a nodule), by a nuclear density 
greater than twice normal and by mild but definite nuclear atypia and 
inconspicuous nucleoli.  Fatty change is noted in 40% of cases, sometimes with 
Mallory bodies. Stromal and portal tract invasion may occur, but vascular 
invasion is quite rare. 
Advanced Hepatocellular Carcinoma  
The tumor cells resemble that of normal hepatocytes typically arranged  
in a trabecular pattern outlined by sinusoids. Histological grading of HCC was 
devised by Edmundson and Steiner nearly 50 years ago; subsequently, other 
similar systems have been proposed. Most tumors are moderately differentiated 
(grades 2 to 3).Without definite evidence of hepatocellular differentiation, a 
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malignant epithelial tumor in the liver should be regarded as a poorly 
differentiated carcinoma that is most likely metastatic.  
HCC is typically associated with little tumor-induced stroma. Significant 
fibrosis occurs in about 5% of cases of scirrhous and fibrolamellar variants of 
HCC. As HCC progresses from a small to an advanced type, the extent of 
sinusoidal capillarization increases. The World Health Organization (WHO) 
recognizes five histological patterns and four cytological variants of HCC.  
Histological Patterns; These patterns are frequently found together in the 
same tumor. Only the fibrolamellar type appears to have prognostic 
significance. The patterns are   
1. Trabecular or sinusoidal 
2. Compact or solid 
3. Pseudoglandular (acinar, adenoid) 
4. Fibrolamellar 
5. Scirrhous 
Cytological Appearance; The tumor cells are usually polygonal and have 
(a) distinct cell membranes (b) a higher nuclear to cytoplasmic ratio compared 
with normal hepatocytes, (c) abundant, finely granular eosinophilic cytoplasm 
and (d) a round nucleus often containing coarse chromatin and a thickened or 
 26 
irregular nuclear membrane. Although nucleoli are often prominent, this is not 
a consistent finding. The cytological variants of HCC include:  
1. Pleomorphic or giant cell   
2. Clear cell 
3. Oncocyte-like  
4 .Sarcomatoid or spindle cell  
Several different types of eosinophilic hyaline globules, both intra- and 
extracellular, have been described in 10% to 15% of HCCs. They often display 
immunoreactivity for AFP, A1AT, or alpha1-antichymotrypsin (A1ACT). The 
finding of a hepatic tumor with immunoreactivity for AFP is very suggestive of 
HCC and its presence in poorly differentiated tumors may be of particular 
diagnostic utility. However, other neoplasms (such as HBL; adenocarcinomas 
of the pancreas, stomach and lung and yolk sac tumor) may demonstrate this 
antigen. Measuring serum AFP by modern techniques is more sensitive than 
finding immunohistochemical evidence of AFP in tumor tissue.     
Fibrolamellar Hepatocellular Carcinoma   
The tumor consists of large polygonal cells with abundant granular 
eosinophilic cytoplasm (oncocytes), sharply defined cell borders and a large 
vesicular nucleus with a prominent nucleolus. These neoplastic hepatocytes are 
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separated into nests, columns or variably sized sheets by parallel, hyalinized 
bands of relatively acellular collagen (thus the term “fibrolamellar”) that may 
contain small, thick-walled arteries. Mitoses are infrequent.  
Combined Hepatocellular Carcinoma–Cholangiocarcinoma   
Less than 5% of primary hepatic carcinomas demonstrate an intimate 
admixture of both unequivocal HCC and cholangiocarcinoma (hence combined 
HCC-CC), the latter characterized by cells with a cuboidal to columnar shape, 
less abundant and more amphophilic cytoplasm, less conspicuous nucleoli, 
gland formation and mucin production. Separate HCC and CC, no matter how 
closely situated in the liver are best considered “collision tumors” rather than 
combined HCC-CC. A tumor that has foci only suggestive but not diagnostic of 
both HCC and CC should be considered an undifferentiated carcinoma and is 
likely a metastasis. A “biliary type” CK profile has been suggested as helpful in 
defining the cholangiocarcinoma component. 
Hepatoblastoma   
HBL represents the most common primary hepatic tumor in children.  
The serum AFP level is elevated in up to 90% of cases, usually with very high 
titers. HBLs may be classified as either epithelial (56%) or mixed epithelial–
mesenchymal (44%). The epithelial component  is usually divided into 
irregular lobules by collagenous septa. Foci of extramedullary hematopoiesis 
may be found in the sinusoids of either the fetal or the embryonal patterns.   
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1. Fetal pattern (31%): In this pattern the hepatocytes are similar in size to 
or smaller than those seen in the adjacent non neoplastic liver. They 
have a slightly higher nuclear to cytoplasmic ratio and inconspicuous 
nucleoli. The tumor cells are arranged in trabeculae two to three cells 
thick, separated by sinusoids lined by endothelial cells. Portal tracts, bile 
ducts and ductules are absent. 
2. Embryonal pattern (19%): Compared with the fetal pattern, the tumor 
cells have more poorly defined cell borders, more basophilic cytoplasm, 
a higher nuclear to cytoplasmic ratio, coarser chromatin, and more 
prominent nucleoli.  
3. Macrotrabecular pattern (3%): This pattern is characterized by 
trabeculae that are ten or more cells.  
4. Small-cell undifferentiated pattern (3%).  
5. Mixed epithelial and mesenchymal pattern (44%):The primitive 
mesenchymal component has oval to spindle-shaped cells with little 
cytoplasm, often located within or adjacent to the neoplastic epithelial 
component.  
Intrahepatic Cholangiocarcinoma  
 Microscopic Features: Most cases of CC demonstrate a variable degree 
of glandular (ductal, tubular) differentiation and mucin production with a 
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moderate amount of densely fibrotic stroma. In well-differentiated cases, the 
glands are lined by cuboidal to low columnar cells that contain a moderate 
amount of pale sometimes slightly granular cytoplasm. The size of the cells and 
nuclei is generally smaller and the nucleoli less prominent than in HCC. Bile is 
not produced by cholangiocarcinomas. A trabecular pattern may be found 
simulating HCC, but collagenous stroma, rather than sinusoids surround the 
cords of tumor cells; bile canaliculi as well as bile are absent.  
 Making the distinction between cholangiocarcinlma and metastatic 
adenocarcinoma, particularly from the gallbladder, pancreas, extrahepatic 
biliary tree and breast is impossible on histological grounds. At present, there 
are no specific tumor markers useful in distinguishing cholangiocarcinoma 
from other forms of adenocarcinoma.  
Metastatic tumors in the liver 
 Metastatic tumor accounts for about 98% of all hepatic malignancies 
and is found in nearly 4% of all liver biopsies. Forty percent of patients dying 
from cancer have hepatic metastases. In the cirrhotic liver, however, primary 
hepatic malignancies (nearly always HCC) are more common than metastatic 
tumors representing 77% and 23% of all hepatic malignancies respectively . 
The sensitivity of ultrasonography and CT for detecting metastatic disease is 
about 85% but it is considerably lower when lesions are few and smaller than 2 
cm. Carcinomas of the lung, breast, colon and pancreas account for the 
 30 
overwhelming majority of hepatic metastases in adults, whereas metastatic 
neuroblastoma, Wilms’ tumor, and rhabdomyosarcoma are most common in the 
pediatric age group. Carcinomas of the pancreas, stomach and lung are the 
tumors most likely to be found in adults in conjunction with hepatic metastases 
and an inapparent primary site. In general, patients with hepatic metastases die 
within 1 year, but notable exceptions include patients with metastatic 
neuroendocrine neoplasms and neuroblastoma and a select subgroup 
(approximately 5%) of patients with metastatic colon carcinoma. In the latter 
instance, 5-year survival rates of 25% to 39% have been reported after 
resection of hepatic metastases. 
Hepatic Adenoma (HCA) 
Microscopic Features include normal-sized or slightly enlarged 
hepatocytes in cords that are one to two cells thick. Bile ducts, ductules and 
portal tracts are absent within HCA. The hepatocytes of HCA possess 
acidophilic, clear or vacuolated cytoplasm. The nuclei are bland with 
inconspicuous nucleoli. The so-called oncocytic liver cell adenoma may 
represent an oncocytic variant of HCC.  
The absence of a classic trabecular pattern, a relatively low nuclear to 
cytoplasmic ratio and the absence of vascular invasion aid in making the 
histopathologic distinction from HCC.   
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5. FINAL DIAGNOSIS BASED ON MULTIDISCIPLINARY 
APPROACH 
 Close clinicopathological correlation is mandatory for enhancing the 
yield of FNA diagnoses and the reduction of indeterminate reports. A benign 
cytodiagnosis obviates unnecessary surgery. Surgical resection is indicated for 
any resectable malignant hepatic mass be it primary or secondary. In 
unresectable malignant lesions, a precise cytohistological typing is crucial for 
appropriate alternative therapy. There is no reliable data to establish the risk of 
needle track seeding. Only 0.006% has been regarded by many authors.24,25,26 
Tissue procurement by FNA under radiological guidance and cytological 
interpretation of the aspirated material  has improved the diagnosis of 
malignnacies of the liver. 
FINE NEEDLE ASPIRATION VERSUS  CORE NEEDLE BIOPSY 
Fine needle aspiration :  
Fine needle aspiration  is useful for (i) cirrhotic patients with poor liver 
function with risk of bleeding; (ii) liver masses with obstructive jaundice and 
risk of bile leakage, those near big vessels, or where there is need to go through 
bowel; (iii) small (<2 cm diameter), deep-seated and difficult to approach 
nodules that require close patient co-operation during the procedure; (iv) 
representative sampling of sizeable lesions by re-direction of the needle and 
multiple passes and (v) on-site rapid assessment of adequacy and rendering of 
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provisional diagnosis, as well as for appropriate triage of tissue specimens for 
ancillary studies (e.g. microbiology, flow cytometry, genetic testing, molecular 
diagnostics, cell block preparation and electron microscopy). 
Core needle biopsy: 
Core needle biopsy, with the availability of more material, provides 
tissue for histological and immunohistochemical studies, especially in two 
major areas of diagnostic difficulties namely in the (i) differentiation of well 
differentiated HCC from benign hepatocellular nodules; and (ii) separation of 
HCC from Cholangio carcinoma and metastases. 
Consensus: The diagnostic accuracy in terms of sensitivity, specificity 
and positive predictive value of FNA for HCC is almost similar to that of core 
needle biopsy. The accuracy rate is highly operator-dependent and increases 
with both techniques combined. The specificity and positive predictive value of 
FNA in the diagnosis of malignant hepatic lesions has been shown to be close 
to 100% in most studies.27,28,29,30 These results are comparable to the accuracy 
of core needle biopsy. In a comparative study, it was reported that both 
procedures FNA and core needle biopsy, had the same diagnostic accuracy of 
78% when considered separately and of 88% when considered in 
combination.31 The conclusion was that the great advantage of combining the 
two techniques was the reduction in false negative results. Using larger caliber 
cutting needle, biopsies can be associated with a greater number of 
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complications.30 Many studies have shown improved diagnostic yield and 
accuracy of FNA using the combined cytohistological approach.32,33 
FNA can provide rapid on-site diagnosis when the smears are stained 
with Diff-Quik or Ultra-fast Papanicolaou stain.34 In the era of rising costs in 
medical practice and higher patient/practitioner/institution expectations of 
efficiency and faster turn-around time, FNA can obviate the need to wait for 
tissue processing if accurate cytological diagnoses can be rendered. Another 
cost-saving advantage, especially for less developed countries is that smears 
are cheap, convenient and easy to prepare as long as there is an experienced 
person to interpret them. 
Considering the overall advantages and cost-analysis, FNA can be 
suggested as the initial method of choice for evaluation of focal liver lesions in 
most clinical settings. 
Diagnostic utility of immunohistochemistry  
There are two major applications for immunohistochemical markers in 
the diagnostic workup of focal liver lesions. One is to decipher the exact 
histogenetic origin of obvious tumor nodules i.e the histological typing and the 
primary site. It may not always be possible to distinguish between the poorly 
differentiated entities of HCC, cholangiocarcinoma and metastatic carcinomas. 
Adenocarcinomas occurring in the liver may be metastatic or primary in origin. 
Of interest lately is the increasing documentation of AFP-producing 
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extrahepatic hepatoid/non-hepatoid carcinomas that have a propensity for 
vascular invasion and liver metastases. The immunoprofile of these tumors, 
originating mostly in the GIT and lungs, is almost identical to that of HCC. 
Serum AFP levels tend to be very high.  For ascertainment of malignancy in 
hepatocellular nodules, the antibody panel should comprise at least AFP, pCEA 
or CD10, and CD34.35,36,37 The panel should comprise at least AFP, pCEA or 
CD10, and CD34.35,36,37  
• CD10  should be included if the histogenesis of the tumor is to be 
studied. The sensitivity of CD10 (68.3%) is far better than immuno-
staining for AFP (23.8%) but less sensitive than pCEA (95.2%) in the 
diagnosis of HCC  
• AFP is fairly specific but not sensitive for HCC. Tissue AFP 
immunoreactivity is expected in HCC but it may be patchy and minimal. 
Sensitivity is about 50% (range, 20–75%) and is low at both ends of the 
histologic spectrum of HCC. A study of 56 patients with small HCC (<2 
cm diameter) showed AFP-positivity in 44.6% of the tumors. A variable 
staining pattern may be encountered with CHCC-CC.   
• pCEA. There are two patterns of staining in HCC – canalicular and/or 
diffuse cytoplasmic staining. Bile located within neoplastic cells or 
tubular lumina is pathognomonic of HCC. Routine 
immunohistochemical testing using unabsorbed polyclonal anti-CEA 
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antiserum or certain monoclonal CEA (m-CEA) antibodies, each of 
which cross-reacts with canalicular biliary glycoprotein 1, demonstrates 
bile canaliculi (canalicular pattern) in 70% to 80% of HCCs. 
Canalicular CEA staining remains the most useful and most thoroughly 
investigated immunohistochemical marker in the differential diagnosis of HCC, 
although one drawback is that about 50% of poorly differentiated tumors lack 
immunoreactivity.  
• Hep Par 1 (Hepatocyte antigen) Hep Par-1 is a recently described 
monoclonal antibody that reacts with a hepatocyte-specific epitope, the 
exact nature of which is unknown. Its staining pattern suggests organelle 
localization, possibly mitochondrial . Studies from the University of 
Pittsburgh have shown performance characteristics similar to p-CEA 
with 82% sensitivity and 90% specificity. Drawbacks to the use of this 
antibody are that it is not commercially available, occasional staining of 
non-HCC malignancies has been described and that there are false 
positives due to staining of trapped non neoplastic hepatocytes and 
insensitivity of identification of poorly differentiated HCC (50%)  
However, not all HCC stain uniformly and not all Hep Par 1-positive 
tumors are of hepatocellular origin or arise in the liver. MRN, DN, FNH 
and LCA tend to exhibit 100% positivity. Hence, this antibody has no 
discriminant value in the evaluation of the biological status of well-
differentiated hepatocellular nodular lesions. 
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• Cytokeratins   (CK 7, 8, 18, 19, 20; CAM 5.2; AE1/AE3). Mature 
hepatocytes stain with CK 8 and 18 and CAM 5.2 but not with CK 7, 
19 or 20 or AE1/AE3.Bile ducts express CK 7 and 19.  CAM 5.2 is 
the most reliable cytokeratin antibody for HCC. AE1/AE3 negativity 
is expected in hepatocellular lesions. Focal CK 7 and 19 positivity 
can be seen in high-grade HCC. HCC is generally CK 20 negative. 
HCCs (up to 60%, particularly moderate and poorly differentiated 
tumors) and even non neoplastic hepatocytes have been found to 
frequently modify their CK expression and express non hepatocyte 
CK (other than CK 8 and 18) therefore limiting their diagnostic 
utility 
• CD34 highlights regions of sinusoidal capillarization where there is 
basement membrane material deposition. Diffuse sinusoidal CD34 
reactivity is seen in HCC, even in small WD-HCC. However, significant 
reactivity is also seen in LCA and some FNH. 
• Erythropoiesis-associated antigen (ERY-1; not commercially 
available) was found in 89% of HCCs in one study is a sensitive marker 
for hepatocytic differentiation and is part of the antibody panel for 
distinguishing HCC from CC and metastases 
In summary, many investigators currently use a panel of p-CEA 
(canalicular pattern), m-CEA and AFP antibodies when evaluating 
diagnostically challenging cases. HepPar-1 and ERY-1 may prove to 
complement and enhance the performance characteristics of this approach. 
 37 
MATERIALS AND METHODS 
This prospective study was undertaken in the Institute of Pathology, 
Madras Medical College from June 2006 to July 2008. Fifty two patients who 
were detected to have focal liver lesions by US/CT imaging were chosen and 
subjected to FNA followed by trucut biopsy under US guidance. The 
aspirations were performed either to confirm or exclude suspected primary or 
metastatic liver malignancy based on clinical findings in symptomatic patients. 
All patients signed informed consent prior to aspiration and the study protocol 
conformed to the ethical guidelines of the Declaration of Government General 
Hospital, as reflected in a prior approval by the Hospital’s Human Research 
Committee. 
Inclusion and exclusion criteria were used to select the patients for 
interventional procedure.   
INCLUSION CRITERIA: 
Candidates for liver biopsy must be carefully selected, as this procedure, 
by nature, is invasive. In all cases, noninvasive imaging studies such as CT 
scan or ultrasound are obtained first. Though there are many indications for 
liver biopsy, this prospective study focusses on the radiologically (CT/US) 
proven cases of focal liver lesions.   
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EXCLUSION CRITERIA 
1. Impaired hemostasis with prothrombin time more than 3 seconds over 
control, PTT more than 20 seconds over control, thrombocytopenia and 
markedly prolonged bleeding time (Mahal et al38 in 1979 noted 22 
bleeding episodes in3800 percutaneous liver biopsies) 
2. Severe anemia (Hb <8 g/dL) 
3. Local infection near needle entry site, such as right sided pleural 
effusion or empyema, right lower lobe pneumonia, local cellulitis, 
infected ascites or peritonitis 
4. Tense ascites (low yield technically, risk of leakage)5. High-grade 
extrahepatic biliary obstruction with jaundice (increased risk of bile 
peritonitis) 
5. Septic cholangitis 
6. Possible hemangioma 
7. Possible echinococcal (hydatid) cyst 
8. Uncooperative patient 
9. Poor performance status 
10. Advanced malignancy 
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PATIENT PREPARATION: 
Procedures and risks of the procedure were explained and informed 
consent was obtained. Procedure entailed overnight hospitalization and the 
patients needed to stay in the hospital for 1-2 days post biopsy for observation. 
All aspirin products and non steroidal agents were discontinued at least 5 days 
beforehand. Injection vitamin K was given in jaundiced and liver failure 
patients. The patients were kept in empty stomach after midnight, the day prior 
to the procedure. Screening laboratory studies including CBC, PT/PTT, BUN, 
bleeding time, coagulation time and typing and crossmatching for possible 
transfusion, electrolytes and liver function tests, viral markers and serum alpha 
feto protein  were done  24-48 hours in advance.    
EQUIPMENT: Disposable automated Trucut biopsy gun –18 Gauge 
needle with 2 cm throw length, designed to cut out cores of tissue. Specimens 
obtained with this needle were less fragmented, even in the cirrhotic liver and 
thus a high success rate. Specimen was obtained using suction/aspiration into a 
10 ml syringe. Trucut needle is a modernized Vim-Silverman needle.  
TECHNIQUE:  
Patient was laid supine in bed with right hand behind his head. Liver 
margins were estimated by ultrasound. Two approaches are popular, 
transthoracic (intercostal) or subcostal (anterior). With the former, biopsy site is 
identified along the midaxillary line in the center of hepatic dullness, usually 
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the eighth or ninth intercostal space.This approach avoids other abdominal 
organs but always penetrates the pleura.With the subcostal approach, the biopsy 
site lies below the bottom rib anteriorly  and is used when a liver mass is easily 
palpable below the right costal margin. The risk of visceral laceration is higher 
and this approach is infrequently used. 
A wide area was prepped and draped in sterile fashion. The skin was 
anaesthetized with 1% lidocaine, then deeper structures such as subcutaneous 
tissue, intercostal muscles and diaphragm were infiltrated in that order. A small 
superficial incision was made with a No 11 blade at the needle entry site to 
facilitate needle insertion. The first needle pass should sample the centre of the 
lesion since this will reduce contamination by cells from surrounding normal 
liver.  The centres of large lesions may occasionally be necrotic and hence may 
not render diagnostic material.  If the first pass yielded only necrotic debris 
and/or inflammatory cells, the second pass should be made close to the edge 
but well within the target. Under US guidance, an outer guide needle of larger 
diameter and 10 cm long was first introduced through the superficial layers. 
This outer needle will not only ensure needle stability, but will also allow 
multiple passes of the needle without inconvenience to the patient. The fine 
needle of 20 gauge was attached to a disposable syringe and was passed 
through it. When the tip of the fine needle was correctly located within the 
lesion by US, negative pressure was applied and the needle advanced steadily 
for 1-2 cm and moved back and forth. With the needle still in position negative 
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pressure was released and needle withdrawn. The patient was asked to suspend 
respiration during advancement of the needle. Usually several passes of the 
needle were performed in slightly different directions to ensure representative 
sampling. The material in the needle was expelled on to glass slides and 
smeared immediately. 
Through the outer needle, 18 gauge automated biopsy gun of 2 cm throw 
length was inserted and patient asked to suspend respiration. The position of 
the stylet was confirmed by US and then the device was fired. A 2.5 cm core of 
liver was aspirated and needle withdrawn. Several passes of the biopsy needle 
(2-3) were performed to minimize sampling bias. 
SPECIMEN: 
At least two to three liver cores, each more than 2 cm in length was 
routinely fixed in 10% buffered formalin, specimen processed and the tissues 
stained with  hematoxylin and eosin. 
Cytological preparation - fluid from aspirating syringe was smeared on 
clean microscope slides and sent to Cytology Laboratory.Smears were air-dried 
and stained with May-Grunwald-Giemsa as well as fixed in 95% alcohol and 
stained by the Papanicolaou method and hematoxylin and eosin.                                                 
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AFTERCARE: 
Patients were monitored in a recovery area with frequent examination of 
vital signs (blood pressure, pulse) post biopsy. If no complications were 
apparent, they were transferred back to ward in stretcher. Strict bed rest was 
enforced for 24 hours. For the first 2 hours, patient was positioned on his right 
side. Vital signs were checked frequently. Diet was restricted to clear liquids for 
several hours, then full liquids as tolerated. Acetaminophen was usually 
sufficient for pain control. 
COMPLICATIONS:  
Based on several large series, serious morbidity has been estimated at 
0.1% to 0.2%. Fatality rates have ranged from 0% to 0.17%, both figures being 
derived from studies involving >20,000 biopsies each. The more commonly 
seen complications are: 
1. Pain was the most common adverse event, noted in almost all the cases.  
2. Hemorrhage - minor episodes were common. Self-limited oozing from 
the puncture site persisted for approximately 1 minute, but with loss of 
only 5-10 ml blood. Significant hemorrhage was less frequent. But is the 
most common cause of death from liver biopsy. Several series have 
estimated an incidence of approximately 0.2%, but Sherlock (1984) 
reported 40 patients out of 6379 required transfusion for intraperitoneal 
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bleeding.39 Bleeding usually results from a tear of a distended portal or 
hepatic vein and vascularized tumor. In our study we did not encounter 
any massive bleeding episodes. 
3. Bile leakage with peritonitis - associated with severe obstruction of the 
larger bile ducts. This is felt to result from laceration of a small, 
distended duct or from puncture of the gallbladder.  
4. Laceration of internal organs and viscera  
5. Others: right-sided pneumothorax.  
 44 
RESULTS 
This prospective analysis was done on fifty two patients, among which 
39 were males accounting to 75% of our study population with focal liver 
lesions and 13 were females which was 25% ( Table 1) 
Table 1 : STUDY POPULATION – SEX DISTRIBUTION 
 Male Female 
Number of cases 39 13 
Percentage of total  75% 25% 
   
The peak incidence of focal liver lesions was highest in the age group of 
61-70 years in the males and 41-50 years in the females as given in Table 2 and 
figure 2.                                                                                                                                          
Table 2 : STUDY POPULATION – AGE & SEX DISTRIBUTION 
AGE (YRS) MALE FEMALE TOTAL 
1-10  1 1 2 
11-20  0 0 0 
21-30  1 0 1 
31-40  5 4 9 
41-50  3 5 8 
51-60  11 1 12 
61-70  16 2 18 
71-80  2 0 2 
TOTAL 39 13 52 
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 46 
Males formed the majority of the cases reported as Hepatocellular 
carcinoma contributing to 20 of the 24 cases of which 45% were in the sixth 
decade as shown in table 3. The incidence of liver secondaries was also high in 
males (14 cases) and in seventh decade, as that of hepatocellular carcinoma.as 
shown in table 4.  
Table 3 : HEPATOCELLULAR CARCINOMA- AGE & SEX 
DISTRIBUTION 
AGE (YEARS) MALE FEMALE TOTAL 
31-40 2 2 4 
41-50 2 2 4 
51-60 9 0 9 
61-70 6 0 6 
71-80 1 0 1 
TOTAL 20 4 24 
 
Table 4 : LIVER SECONDARIES – AGE & SEX DISTRIBUTION 
AGE (YEARS) MALE FEMALE TOTAL 
31-40 3 2 5 
41-50 1 3 4 
51-60 2 0 2 
61-70 8 1 9 
TOTAL 14 6 20 
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Fig 3 
 
Fig 4  
 
 
 48 
The damage to the liver by various focal lesions was  clinically 
manifested as jaundice in 12cases (23%), liver failure in 6 cases (11.5%), portal 
hypertension in 10 cases (19.2%), loss of weight and loss of appetite in 23 
cases (44.2%). Similar results were found in both HCC and metastatic liver 
lesions. 
Table 5 : STUDY POPULATION – CLINICAL MANIFESTATIONS 
Clinical features Number of cases % 
Jaundice 12 23.08 
Liver failure 6 11.54 
Portal Hypertension 10 19.23 
Loss of appetite/Loss of weight 23 44.23 
 
Fig 5 
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Table 6 : CLINICAL MANIFESTATIONS IN HEPATOCELLULAR 
CARCINOMA 
                                    
Clinical features Number of cases % 
Jaundice 10 19.23 
Liver failure 4 7.69 
Portal hypertension 9 17.31 
Loss of appetite/loss of weight 17 32.69 
 
Fig 6 
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Table 7 : STUDY POPULATION – LAB INVESTIGATIONS 
Lab investigations Number of cases % 
Increased bilirubin 7 13.4 
HBS Ag 2 3.85 
Increased SGOT/ SGPT 11 21.15 
Increased SAP 7 13.4 
HBS Ag- Hepatitis B surface antigen 
SAP- Serum Alkaline Phosphatase                         
The abnormalities in liver function tests in our study population are 
shown in table 7 and figure 7. Increased bilirubin was seen in 7 cases (13.5%), 
increased SGOT/SGPT in 11 cases (21%) and increased serum alkaline 
phosphatase in 7 cases (13.5%). Viral markers were done for all cases and 2 
cases showed positivity. Similar results were found in both HCC and metastatic 
liver lesions. 
Fig 7                            
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Among the 52 cases of focal liver lesions subjected to US guided FNA 
and biopsy, histopathological diagnosis was  primary hepatocellular carcinoma 
in 24 cases (46.15%), followed by secondary adenocarcinomatous deposits in 
16 cases (30.77%) and hepatoblastoma in 2 cases (3.85%). Other interesting 
cases were Cholangiocarcinoma (1.92%), hepatic adenoma (1.92%), secondary 
synovial sarcomatous deposit (1.92%) and secondary squamous cell 
carcinomatous deposits (1.92%) each  contributed to one case. Definitive 
typing of malignancy could not  be done in 2 cases (3.85%), for which 
immunohistochemistry was done. Biopsy material  was inadequate and showed 
no evidence of malignancy in 2 cases (3.85%). One case showed evidence of 
liver cell dysplasia (1.92%) only. Another case which had definitive 
radiological evidence of malignancy, proved to be an abscess (1.92%) by both 
HPE and FNA , the details of which is shown in table 8 and figure 8 . 
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Table 8: DISTRIBUTION OF FOCAL LIVER LESIONS - 
HISTOPATHOLOGY 
LESION NUMBER OF 
CASES 
Percentage  of 
total 
% 
HEPATOCELLULAR CARCINOMA 24 46.15 
ADENOCARCINOMA 16 30.77 
SQUAMOUS CELL CARCINOMA 1 1.92 
SYNOVIAL SARCOMA 1 1.92 
SECONDARIES NOT SPECIFIED 1 1.92 
CHOLANGIOCARCINOMA 1 3.85 
HEPATIC ADENOMA 1 1.92 
HEPATOBLASTOMA 2 1.92 
CARCINOMA NOT SPECIFIED 1 1.92 
INADEQUATE 2 3.85 
OTHERS 2 3.85 
TOTAL 52 100% 
 
Fig 8. 
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By FNA, 23 cases (44.23%) were diagnosed to be HCC, 15 cases 
(28.84%) were secondary adenocarcinomatous deposits and 2 cases (3.84%) 
were hepatoblastoma. Cholangiocarcinoma (1.92%), hepatic adenoma (1.92%), 
secondary synovial sarcoma deposit (1.92%) and secondary squamous cell 
carcinomatous deposit (1.92%) each contributed to one case. As with 
histopathology, in FNA also  definitive typing of malignancy could not  be 
done in 2 cases (3.84%) and in one case (1.92%) the smear showed evidence of 
secondaries liver but could not be specified. Another 4 smears (7.69%) showed 
no evidence of malignancy, which might be due to non representative sampling. 
Another case (1.92%) which had definitive radiological evidence of 
malignancy, proved to be an abscess by both HPE and FNA, the details of 
which are shown in table 9.  
Table 9  : DISTRIBUTION OF FOCAL LIVER LESIONS - FNA 
LESION NUMBER OF 
CASES 
PERCENTAGE 
OF TOTAL 
HEPATOCELLULAR CARCINOMA 23 44.23% 
ADENOCARCINOMA 15 28.84% 
SQUAMOUS CELL CARCINOMA 1 1.92% 
SYNOVIAL SARCOMA 1 1.92% 
SECONDARIES NOT SPECIFIED 1 1.92% 
CHOLANGIOCARCINOMA 1 1.92% 
HEPATIC ADENOMA 1 1.92% 
HEPATOBLASTOMA 2 3.84% 
CARCINOMA NOT SPECIFIED 2 3.84% 
UNREPRESENTATIVE/INADEQUATE 4 7.69% 
OTHERS 1 1.92% 
TOTAL 52 100% 
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Considering histopathology as the gold standard for definitive diagnosis 
of any lesion, of the 52 cases of our study, 47 cases correlated well with the 
FNA. Thus in 90.38% of focal liver lesions, FNA findings were consistent with 
that of HPE. Of the 24 cases diagnosed to be HCC by biopsy, 22 cases were 
also diagnosed as HCC by FNA. The percentage of correlation with respect to 
HCC was 91.67%. Of the 16 secondary adeno carcinomatous deposits 
diagnosed by biopsy, 13 cases were found to have correlated well with that of 
FNA (81.25%).The other cases of Cholangiocarcinoma, hepatic adenoma, 
hepatoblastoma, secondary synovial sarcoma deposit and secondary squamous 
cell carcinomatous deposit correlated well with respect to FNA and HPE. 
Another case which had radiological evidence of malignancy, proved to be an 
abscess by both HPE and FNA. For 2 cases for which definitive typing of 
malignancy could not be done by biopsy, FNA was also not contributory and 
IHC was done. Hep Par 1 was the marker used which showed positivity 
indicating probable origin from the hepatocytes. In 2 cases both cytology and 
histopathology were negative for malignancy inspite of radiological findings, 
which might be due to non representative sampling technique. A case of liver 
cell dysplasia was diagnosed by biopsy, though cytology showed evidence of 
adenocarcinoma which probably could be non representative sample.The 
results of correlation are shown in figure 9 and table 10 
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Table 10 : FNA – HISTOPATHOLOGY CORRELATION 
LESION HPE 
(n) 
FNAC 
(n) 
%  of 
Correlation 
HEPATOCELLULAR CARCINOMA 24 22 91.67 
ADENOCARCINOMA 16 13 81.25 
SQUAMOUS CELL CARCINOMA 1 1 100.00 
SYNOVIAL SARCOMA 1 1 100.00 
SECONDARIES NOT SPECIFIED 1 1 100.00 
CHOLANGIOCARCINOMA 1 1 100.00 
HEPATIC ADENOMA 1 1 100.00 
HEPATOBLASTOMA 2 2 100.00 
CARCINOMA NOT SPECIFIED 1 1 100.00 
NEGATIVE 2 2 100.00 
OTHERS 2 2 100.00 
TOTAL 52 47 90.38 
 
Fig 9. 
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Radiological diagnosis of focal liver lesions was unifocal in 22 cases 
(42.31%) and multifocal in 30 cases (57.69%).With respect to HCC, unifocal 
lesions accounted to 41.67% and multifocal  58.33% as given in table 11 and 
12.   The liver secondaries were unifocal lesion in 7 cases (35%) and multifocal 
in 13 cases (65%) as shown in table 13 
Table 11 : RADIOLOGY OF FOCAL LIVER LESIONS 
UNIFOCAL 22 42.31% 
MULTIFOCAL 30 57.69% 
TOATL 52 100% 
 
Fig 10 
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Table 12: RADIOLOGY OF HEPATO CELLULAR CARCINOMA 
UNIFOCAL 10 41.67% 
MULTIFOCAL 14 58.33% 
TOTAL 24 100% 
 
Fig 11                               
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Table 13 : RADIOLOGY OF SECONDARIES 
UNIFOCAL 7 35% 
MULTIFOCAL 13 65% 
TOTAL 20 100% 
 
Fig 12 
 
Radiological correlation with the histological diagnosis was 57.69 % 
with 30 cases of imaging diagnosis correlating well with HPE. 
The liver metastases diagnosed by imaging studies (20cases) had 100% 
correlation with histopathology, which also diagnosed them to be secondaries 
of the liver. Out of 24 cases diagnosed by HPE, only 10 cases were diagnosed 
as HCC  by US/CT  imaging accounting to the correlation of 41.66% .The 2 
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cases diagnosed as  hepatoblastoma in FNA and HPE were also diagnosed as 
the same in CT imaging         
Table 14 : HPE & IMAGING CORRELATION IN LIVER 
MALIGNANCY 
LESION HPE IMAGING % 
HEPATOCELLULAR CA 24 10 41.67 
SECONDARIES 20 20 100.00 
HEPATOBLASTOMA 2 2 100.00 
 
Fig 13 
 
                             
 60 
Table 15 : STATISTICAL ANALYSIS  
Lesion Sensitivity 
(%) 
Specificity 
(%) 
+ve 
predictive 
Value (%) 
- ve 
predictive 
Value (%) 
False 
+ve 
(%) 
False –
ve (%) 
Focal liver 
lesion 
95.7 80 97.8 66.7 20 4.3 
HCC 91.66 96.42 95.65 93.5 3.57 8.34 
Secondaries 85 93.75 89.5 90.9 6.25 15 
 
The sensitivity of FNA in diagnosis of malignancy was 95.7% in our 
study which is in accordance with the sensitivity rates of studies by various 
authors like Pagani, Holm et al , Butler and Smith, Buscatine et al and Fornari 
et al.The specificity in diagnosing malignancy was 80%. False positive rate 
was 20% and false negativity was 4.3%.The low false negativity rate could be 
attributed to the image guidance of the procedure.The  positive predictive value 
was 97.8% and negative predictive value was 66.7%. 
FNA of HCC showed a sensitivity of 91.66% and a specificity of 
96.42% of false positive rate was 3.57%, false negative rate was 8.34%, 
positive predictive value was 95.65% and negative predictive value was 
93.10% 
FNA of secondaries showed a sensitivity of 85%, specificity of  93.75%, 
false positive rate of 6.25%, false negative rate of 15%, positive predictive 
value of 89.47% and  negative predictive value of 90.90%                    . 
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RESULTS OF IMMUNOHISTOCHEMISTRY 
Cytokeratin was applied for almost  all  cases . 
Hep  Par 1   
Hep  Par1  was done for 10 cases. HCC was taken as a control for 
Hep Par1 that showed strong diffuse cytoplasmic granular positivity. The 
cases of hepatic adenoma and hepatoblastoma also showed strong diffuse 
positivity as that of HCC. Cholangiocarcinoma showed negativity for 
Hep Par 1, thus confirming the tissue diagnosis. The usefulness of the 
marker in selected cases is shown in table below; 
 
Sl. 
No. FNA Diagnosis HPE Diagnosis 
Hep 
Par 1 Interpretation 
1. +ve for malignancy +ve for malignancy -ve -ve for HCC 
2. HCC +ve for malignancy ++ HCC 
3. +ve for malignancy Adenocarcinoma +++ HCC 
4. Adenocarcinoma HCC – Tubular Variant +++ 
HCC – tubular 
Variant 
5. Cholangiocarcinoma Cholangiocarcinoma -ve Cholangiocarcinoma 
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HEPATOCELLULAR CARCINOMA –FNA SHOWING BILE PLUGS (100x) 
 
 
 
 
HEPATOCELLULAR CARCINOMA –FNA SHOWING ENDOTHELIAL RIMMING (100x) 
 
 
 
HEPATOCELLULAR CARCINOMA –FNA SHOWING NUCLEAR PLEOMORPHISM (400x) 
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HEPATOCELLULAR CARCINOMA-FNA SHOWING ENDOTHELIAL RIMMING-PAP STAIN 
 
 
HEPATOCELLULAR CARCINOMA-FNA(H&E) SHOWING INTRANUCLEAR INCLUSIONS (400x) 
 
 
 
HEPATOCELLULAR CARCINOMA-FNA(MGG) SHOWING INTRANUCLEAR INCLUSIONS (400x) 
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HEPATOCELLULAR CARCINOMA-HPE (100x) 
 
 
 
 
 
HEPATOCELLULAR CARCINOMA-HPE (400x) 
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SECONDARY ADENOCARCINOMA-FNA (40x) 
 
 
 
 
SECONDARY ADENOCARCINOMA-FNA (100x) 
 
  
 
 
SECONDARY ADENOCARCINOMA-FNA (400x) 
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SECONDARY ADENOCARCINOMA-HPE (100x) 
 
 
 
 
 
SECONDARY ADENOCARCINOMA-HPE (400x) 
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HEPATIC ADENOMA-FNA –(100x) H&E    
 
 
 
 
HEPATIC ADENOMA-FNA –(400x) H&E    
 
 
 
 
HEPATIC ADENOMA-FNA –(400x) MGG  
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HEPATIC ADENOMA-HPE (100x) 
   
 
 
 
 
HEPATIC ADENOMA-HPE (400x) 
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CHOLANGIOCARCINOMA-FNA (400x) 
 
 
 
 
 
CHOLANGIOCARCINOMA-HPE (100x) 
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SECONDARY SYNOVIAL SARCOMA DEPOSIT-FNA (100x) 
 
 
 
 
 
 
SECONDARY SYNOVIAL SARCOMA DEPOSIT-HPE (100x) 
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HEPATOBLASTOMA-FNA (100x) 
 
 
 
 
HEPATOBLASTOMA-HPE (100x) 
 
 
 
 
SECONDARY SQUAMOUS CELL CARCINOMATOUS DEPOSIT-HPE (100x) 
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IMMUNOHISTOCHEMISTRY-Hep Par 1  (100x) 
 
 
 
 
IMMUNOHISTOCHEMISTRY-Hep Par 1  (400x) 
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                                                                  HEPATOCELLULAR CARCINOMA  
 
UNIFOCAL LESION - CECT 
 
 
 
 
 
 
 
 
 
MULTIFOCAL LESION - CECT 
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SECONDARIES  LIVER  
 
UNIFOCAL LESION - CECT 
 
 
 
 
 
 
 
 
 
 
 
 
 
MULTIFOCAL LESION - CECT 
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  HEPATIC ADENOMA  
SPIRAL CT – SAGITTAL SECTION 
 
 
 
 
 
 
SPIRAL CT CORONAL SECTION 
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TRUCUT BIOPSY GUN (18G) AND FINE NEEDLE ASPIRATION 
SYRINGE WITH NEEDLE (20G) 
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                                          DISCUSSION 
Literature supports the usefulness of FNA in diagnosing benign and 
malignant liver lesions. The overall sensitivity varies from 67-100% in 
diagnosing malignant liver lesions. The specificity was 99%. The positive 
predictive value was 99%, whereas the negative predictive value was 71%.   
This was in accordance to our study with sensitivity of 95.7%, specificity of 
80%, positive predictive value of 97.8% and the negative predictive value of 
66.7%. The experiences of some of the authors are given below: 
Table 16 : COMPARISON WITH STANDARD STUDIES 
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Montali et al   1982 108 
 
M 92 100 100 70 
Rosenblatt et al  1982 59 
 
M 94 100 100 80 
Whitlach et al 1984 86 
 
M 87 100 100 76 
Tatsuta et al 1984 41 
 
M 94 96 94 96 
Gabel et al   1986 854 
 
M 88 100 - - 
Servol et al   1988 175 
 
M 80 100 100 76 
Buscatine et al 1990 972 
 
M 91 99 100 77 
Fornari et al   1990 441 M 93 100 100 84 
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Jacobson et al   1983 55 
 
S 100 100 100 100 
Pagani   1983 100 
 
S 95 100 100 56 
Schwerk et al 1983 130 
 
S 92 93 98 77 
Droese et al 1984 100 
 
S 94 100 100 89 
Haubek 1985 380 
 
S 91 100 100 65 
Holm et al 1985 247 
 
S 92 100 100 60 
Bell et al 1986 197 
 
S 67 100 100 45 
Butler & smith  1989 40 
 
S 98 100 100 88 
Edoute et al   1991 321 
 
S 86 98 99 76 
Ohlsson et al  1999 178 
 
S 89 67 98 27 
Our study 
 
52 S 95.7 80 97.8 66.7 
 
S; solid liver lesions: M ;liver masses of any type 
 79 
 
The relationship between size of lesion and proportion in which a 
correct diagnosis was made was studied by Reading et al (1988)40 and correct 
diagnosis was made by FNA in 79% of lesions 1 cm or less in diameter . False 
positive were due to sampling error or are were based on aspiration material 
that often was scanty.With regard to HCC, FNA is accurate with a sensitivity 
rate 80 to 95% and  a specificity of 100%.41,42,43 
Jacobsen et al 1983 , Droese et al 1984 , Hajdu et al  1989, Fornari et al 
1990, Edoute et al 1991 were able to produce the cytological diagnosis which 
corresponds closely to histology of the tumor. 
 There is no agreement as to the superiority of cytology or 
microhistology in the diagnosis of focal liver lesions  
Table 17 
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Wittenberg et al 198244 
 
65 81 73 
Sangalli et al 198945 
 
112 74 82 
Buscarini et al 199046 
 
969 91 94 
Edoute et al 199147 
 
34 32 62 
Rapaccini et al 199448 
 
73 80 61 
Nyman et al 199549 69 62 91 
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Fang-Ying Kuo et al 200450 936 78.4 76.3 
            
From the comparative studies shown above, it is evident that neither 
method has clear advantages and the retrieval rates and tissue typing accuracies 
are fairly similar. 
The cytology may be inadequate in some patients , particularly in those 
with vascular lesions, in fibrotic, dense tumors, in lymphomas and in well 
differentiated primary liver cancer. 
Edoute et al51 in 1991-1996 prospectively studied the accuracy of non 
guided FNA of liver lesions in 107 patients. The sensitivity was 81%, 
specificity 100%, positive predictive value 100%, negative predictive value 
85%.The overall diagnostic accuracy rate was 91%. The relationship between 
non guided FNA (true +ve &false –ve) and type of suspected malignant liver 
lesions demonstrated by different kinds of imaging (Radioisotope, ultrasound, 
CT among 52 patients with malignant liver disease was also studied by them. 
Table 18 : COMPARISON  OF IMAGING FINDINGS  WITH STANDARD 
STUDIES 
AUTHOR UNIFOCAL MULTIFOCAL 
Edoute et al 26% 74% 
Our study 42% 58% 
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  Accuracy of various imaging modalities in diagnosing HCC according 
to Colli et al52 in 2006 is given below:  
Table 19 : COMPARISON  OF IMAGING FINDINGS  WITH STANDARD 
STUDIES 
Imaging 
technique 
No of studies Sensitivity Specificity 
US 14 60 97 
CT 10 68 93 
MRI 9 81 85 
                
In our study the sensitivity of CT was 68% and specificity was 80%. 
Bakshi et al53 in 2006 correlated 41 FNA from pediatric liver SOL with 
clinical, radiological findings and histopathological diagnosis. The overall FNA 
sensitivity was 95%, specificity was 100%, positive predictive value was 100% 
and  negative predictive value was 92.3% and diagnostic accuracy was 
96.9%.In our study, the 2 cases of pediatric liver SOL reported as 
hepatoblastoma in FNA, correlated well with the imaging and histopathological 
diagnosis. 
CJR Stewart et al54 compared the sensitivity and specificity of 
percutaneous FNA and needle core biopsy in the diagnosis of suspected 
abdominal malignancies and observed that combination of these two 
techniques, the sensitivity was 90.7% and the specificity was 100% for both 
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methods and proved that sensitivity increased with image guidance than direct 
aspiration.They proved FNA was 2-24% more sensitive than needle core 
biopsy. 
Yu and Coworkers (1998)55 have studied diagnostic efficacy of FNA 
using an 18 gauge automated cutting needle in small (3cm or less) focal hepatic 
lesions of different pathologies and different sizes (≤1cm; 1-2cm; 2-3cm).The 
sensitivity for diagnosing malignancy was 96%, specificity 100%, positive and 
negative predictive value were 100 and 96% respectively. 
In 1983 Jacobson et al56 compared the coarse needle biopsy versus fine 
needle aspiration biopsy in the diagnosis of focal liver lesions of 55 patients. 
Our study also showed the same results as given below: 
Table 20 : COMPARISON  WITH STANDARD STUDY 
Author No of patients Core needle 
biopsy 
FNAB 
Jacobson et al 1983 55 41malignant 
7-ve 
7-ve 
41 malignant 
7-ve 
7+ve 
Our study 52 46 malignant 
4-ve 
2-ve 
46 malignant 
4-ve 
2+ve 
                    
FNA is an effective and safe method for the diagnosis of focal hepatic 
lesions, with diagnostic accuracy similar to that of CNB. When the 2 
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techniques are combined, the accuracy of the diagnosis of malignancy of focal 
liver lesion increases.57  
Xu GA in 198958 compared the accuracy rate of ultrasound, FNA and 
HPE and the results were found to be higher for FNA (95.2%) than US 
(86.7%).This was in concordance with accuracy rate of  our study( 94.23%). 
Isin Soyuer et al59 in 2003 analysed 17 cytologic and 5 architectural 
features in a series of 320 FNAs from HCC and compared them with 73 FNAs 
with benign lesions and with 705 FNAs from  metastatic carcinoma. The 
sensitivity of FNA for hepatic malignancy was 99.5% and specificity was 
100%. Bile, centrally placed nuclei and intranuclear inclusions were the most 
specific cytologic criteria of HCC with trabecular pattern consisting of 
sinusoidal capillarization and endothelial rimming of the malignant hepatocytes 
as the predominant pattern. In our study also the smears of HCC showed 
similar characteristic features. 
Devi VL et al60  also found that trabecular pattern covered by 
endothelium was the most common pattern in a study of smears of 32 cases of 
FNA of HCC as in our study.   
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CONCLUSION 
 The following are the conclusions arrived by this study  
• Primary hepatocellular carcinoma is the most common malignancy in 
our study (46.15%), followed by metastatic adenocarcinomatous 
deposits (30.77%). 
• Males formed the majority of the cases of focal liver lesions, with peak 
incidence between 61-70 yrs. 
• HPE and imaging correlation is 57.69%. 
• Taking HPE as the gold standard for correct diagnosis, the correlation of 
FNA with HPE diagnosis is 90.68%. 
• With respect to HCC, the correlation of FNA with HPE is 91.67%. 
• Correlation of secondary adenocarcinomatous deposits is 81.25% . 
• The results of image guided FNA in our study: 
                     Sensitivity is 95.67% 
                     Specificity is 80 % 
                     False positive rate is 20%  
                     False negative rate is 4.25% 
Deleted: ¶
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                     Positive predictive value is 97.8% 
               Negative predictive value is 66.7% 
• With application of above parameters the diagnostic accuracy of FNA is 
94.23% 
• There were no major  complications encountered.  
• US guidance increases the accuracy of diagnosing the malignancies  of 
the liver.   
• FNA is useful in the diagnosis of focal liver lesions and trucut biopsy is 
helpful in tumor typing , grading and determination of primary site of 
origin in metastatic lesions. 
• The combination of FNA and trucut biopsy should be considered 
complementary diagnostic techniques.  
• Immunohistochemistry  is helpful in doubtful cases to prove tumour 
origin. 
• The accuracy of diagnosis in FNA and HPE is almost similar indicating 
that the simple and safe technique of US guided FNA is a little superior 
to HPE and in correlation with serum markers could be an effective 
alternative method for biopsy. 
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• From this study it has been proved that FNA technique yielded higher 
number of positive diagnosis of malignancy than obtained with core 
needle, because aspirated material obtained with fine needle, represents 
a considerably  larger area since repeated aspirations are performed in 
various directions. 
Ultrasound guided FNA of liver lesions is a rapid, inexpensive, safe,   
highly accurate and minimally invasive technique for obtaining a tissue 
diagnosis in solid focal lesions of the liver. 
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2 3778/07 7611/07 M 64 - √     √         - - √ - - √ HCC/SEC HCC HCC 
3 5263/07 7596/07 M 35 √ √ √ - √ - - - - - ↑ √ √ √ - HCC HCC HCC 
4 5321/07 7697/07 M 65 - √ - - - - - - - - - √ √ - √ SEC HCC  HCC 
5 5529/07 8021/07 M 60 - √ - - √ - - √ - - ↑ √ √ √ - HCC HCC HCC 
6 5651/07 8261/07 M 72 - - - - √ - - - - ↑ - √ √ √ - HCC +VE  +VE  
7 5827/07 8582/07 F 21 - √ √ - √ - - - - - - √ √ √ - MASS HCA HCA 
8 1125/07 4347/07 F 48 √ √ - - √ - ↑ - - - - - √ - √ SEC ACA ACA 
9 5833/07 8604/07 M 67 - √ - - - - - - - - - √ √ √ - AB HCC HCC 
10 5870/07 8848/07 M 67 - - - - - - - - - - - √ - √ - AB AB AB 
11 5998/07 8897/07 M 37 √ √ - - - - - - - - - √ √ √ - HCC HCC HCC 
12 6019/07 2933/07 M 68 - √ √   √ - - - - - - √ √ - √ HCC HCC HCC 
13 112/08 162/08 M 75 - √ √ - √ - - - - - - √ √ √ - HCC HCC HCC 
14 117/08 144/08 M 56 √ √ √ - - - - - - - - √ √ - √ HCC HCC HCC 
15 922//O7 3441/07 M 60 - √ - - √ - - - +VE - - - √ √ -      HCC HCC HCC 
16 414/08 697/08 F 35 - - - - - - - - - - - √ √ - √ SEC ACA ACA 
17 415/08 698/08 M 32 √ √ √ √ √ - ↑ ↑   - - - √ - √ HCC HCC ACA 
18 875/08 1318/08 F 42 - √ √ - √ - - ↑ - - - √ √ - √ SEC ACA ACA 
19 1012/08 1547/08 F 60 - - - - √ - ↑ ↑ - - - √ - - √ SEC -VE  -VE  
20 1007/08 1553/08 M 70 - √ - - √ - ↑ - - - - √ √ - √ SEC A CA ACA 
21 1047/08 1597/08 F 40 - √ - - √ - - - - - - - √ √ - SEC HCC HCC 
22 5770/08 8521/08 M 47 √ √ - - √ - ↑ - - - - - √ - √ HCC HCC HCC 
23 1224/08 1813/08 F 63 - √ - - √ - - - - - - √ √ - √ SEC -VE  -VE 
 2
24 1250/08 1852/08 M 40 - √ √ - √ - - ↑ - ↑ ↑ - √ - √ SEC ACA ACA 
25 1406/08 2077/08 M 60 - √ √ √ √ - ↑ ↑ - - ↑ √ √ √ - SEC ACA ACA 
26 1376/08 2932/08 M 55 √ √ - - √ - ↑ - - - ↑ √ √ - √ SEC HCC HCC 
27 1398/08 2144/08 M 55 - √ √ √ √ - ↑ ↑ - - ↑ √ - - √ HCC HCC HCC 
28 1532/08 2264/08 F 38 - √ - - √ - - ↑ - - - √ √ √ - SEC ACA ACA 
29 336/07 96/07 M 6 - √ - - - - - - - ↑ - - √ √ - HBL HBl HBL 
30 39/07 147/07 F 10 - √ - - - - - - - - - - √ √ - HBL HBL HBL 
31 1813/08 2702/07 M 70 - - - - - - - ↑ - - ↑ √ √   √ HCC HCC HCC 
32 2266/08 3255/08 M 52 √ √ √ - √ - - - - - ↑ √ √ √   HCC HCC HCC 
33 2346/08 3356/08 M 65 √ √ - - √ - ↑ - - - - √ √ - √ SEC 2*CA 2*CA 
34 2450/08 3440/08 M 70 - √ - - √ - - - - - - √ √ √ - SEC 2*SS 2*SS 
35 2504/08 3487/08 F 65 - √ - - √ - - - - - - - √ - √ SEC ACA ACA  
36 2540/08 3511/08 F 41 - √ - - √ - - - - - - √ √ - √ SEC HCC HCC 
37 2503/08 3517/08 M 60 √ √ √ √ √ - ↑ - +VE - ↑ √ √ - √      HCC HCC HCC 
38 2980/08 4065/08 M 62 - √ - - - - - - - - - √ √ √ - HCC ACA ACA 
39 3109/08 4280/08 M 69 - √ - - - - - ↑ +VE - - √ √ - √      SEC ACA ACA 
40 3222/08 4409/08 M 40 √ √ - - √ - ↑ ↑ - - - √ - - √ HCC ACA ACA 
41 3258/08 4435/08 M 68 - √ - - - - - - - - - - √ - √ HCC ACA LCD 
42 3272/08 4455/08 M 45 - √ - - √ - - ↑ - ↑ ↑ √ √ - √ HCC/SEC ACA HCC 
43 3366/08 4527/08 F 37 - - - - - - - ↑ - - ↑ - √ √ - HCA/FNH HCC HCC 
44 3645/O8 4957/08 F 50 - - √ - √ - -- - - - - √ √ - √ SEC HCC HCC 
45 3574/08 4875/08 F 45 √ √ - - - - - - - - - - √ √ - CCA CCA CCA 
46 3536/08 5101/08 M 55 √ √ - √ √ - ↑ ↑ - - ↑ - √ - √ HCC HCC HCC 
47 1850/08 5345/08 M 55 √ √ - - - - - - - - - - √ - √ SEC SCC SCC  
48 4205/08 5770/08 M 55 √ √ √ √ √ - ↑ - - - - √ √ - √ SEC HCC HCC 
49 2634/07 7205/07 M 68 √ √ - - √ - ↑ ↑ - ↑ ↑ - √ √ - HCC -VE  HCC 
50 2712/07 7286/O7 M 50 √ √ √ √ √ - ↑ ↑ - - ↑ - √ - √ SEC -VE  ACA 
51 3108/08 4214/08 M 64 - √ √ √ √ - ↑ ↑ - - ↑ √ √ √   SEC ACA ACA 
52 5254/08 7068/08 M 67 - √ - - √ - ↑ - - - - - √ - √ HCC ACA ACA 
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KEY TO MASTER CHART 
 
HCC  - Hepatocellular Carcinoma 
 
ACA  - Adenocarcinoma 
 
HCA  - Hepatic Adenoma 
 
HBL  - Hepatoblastoma 
 
SS  - Synovial Sarcoma 
 
SCC  - Squamous Cell Carcinoma 
 
SEC  - Secondaries 
 
CaNS  - Carcinoma Not Specified 
 
AB  - Abscess 
 
LCD  - Liver Cell Dysplasia 
 
CA  - Carcinoma 
 
FNA  - Fine Needle Aspiration 
 
HPE  - Histopathological Examination 
 
LOA  - Loss of Appetite 
 
LOW  - Loss of Weight 
 
PHT  - Portal Hypertension 
 
SAP  - Serum Alkaline Phosphatase 
 
SGOT - Serum Glutamate Oxaloacetate Transaminase 
 
SGPT  - Serum Glutamate Pyruvate Transaminase 
 
HBsAg - Hepatitis B Surface Antigen  
 
AFP  - Alfa Fetoprotein 
 
US  - Ultra Sound 
 
CT  - Computerised Tomography 
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                                         PROFORMA 
 
Name:                                       Age:                       Sex:                IP No:   
 
Address:                                   Ref unit: 
 
History: 
1 Smoker  
2 Alcoholic  
3 Drugs  
4 DM/HT/TB  
5 Family H/O  
 
 
 
 
Symptoms: 
 
1. Pain 
2. Fever 
3. Jaundice 
4. Loss of weight/loss of appetite 
5. S/S of portal hypertension 
6. S/S of liver failure 
7. Palpable mass 
8. Asymptomatic 
 
General Examination: 
 
1. Anemia 
2. Jaundice 
3. Lymphadenopathy 
4. Ascites 
5. Portal hypertension 
 
Local Examination: 
 
1. Hepatomegaly 
2. Other masses 
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           Investigation: 
 
1. Complete Hemogram 
2. Coagulation profile 
3. LFT 
4. Urine 
5. Viral markers 
6. Serum AFP 
7. USG: 
 
8. CT: 
 
9. FNAC: 
 
10. Trucut biopsy: 
 
Diagnosis: 
 
Complication: 
 
Treatment: 
